| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/19/2013 | US20130243767 Bispecific molecule binding tlr9 and cd32 and comprising a t cell epitope for treatment of allergies |
| 09/19/2013 | US20130243763 TREATMENT OF HIDRADENITIS SUPPURATIVA (HS) USING TNFalpha ANTIBODIES |
| 09/19/2013 | US20130243761 Methods for prevention and treatment of inflammation using anti-chemokine antibodies |
| 09/19/2013 | US20130243758 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| 09/19/2013 | US20130243757 Method for cancer detection |
| 09/19/2013 | US20130243756 Methods for Treating Diseases and HSV Using Antibodies to Aminophospholipids |
| 09/19/2013 | US20130243755 Novel human ulip/crmp protein and use thereof in diagnosis and treatment of cancers and paraneoplastic neurological syndromes |
| 09/19/2013 | US20130243753 Anti-axl antibodies and methods of use |
| 09/19/2013 | US20130243751 Glycoconjugates and their use as potential vaccines against infection by shigella flexneri |
| 09/19/2013 | US20130243750 Anti-ige antibodies and methods using same |
| 09/19/2013 | US20130243749 Humanized Monoclonal Antibodies and Methods of Use |
| 09/19/2013 | US20130243731 Oncolytic adenoviral vectors coding for monoclonal anti-ctla-4 antibodies |
| 09/19/2013 | US20130243724 Compositions and methods for inducing migration by dendritic cells and an immune response |
| 09/19/2013 | US20130243723 Vaccine immunotherapy |
| 09/18/2013 | EP2639243A1 Anti single-strand type-iv collagen polypeptide antibody, and pharmaceutical, or agent for diagnosing, preventing or treating tumours, containing same |
| 09/18/2013 | EP2639242A2 Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| 09/18/2013 | EP2638916A1 Novel binding molecules with antitumoral activity |
| 09/18/2013 | EP2638907A2 Combinations of an anti-HER2 antibody-drug conjugate and lapatinib |
| 09/18/2013 | EP2638895A2 Circulation of components during homogenization of emulsions |
| 09/18/2013 | EP2638072A2 Fusion proteins for hiv therapy |
| 09/18/2013 | EP2638070A1 Methods and compositions for neural disease immunotherapy |
| 09/18/2013 | EP2638067A2 Subcutaneously administered anti-il-6 receptor antibody |
| 09/18/2013 | EP2638066A2 Antibody scaffold for homogenous conjugation |
| 09/18/2013 | EP2638065A1 Actriia binding agents and uses thereof |
| 09/18/2013 | EP2638062A1 New adjuvant |
| 09/18/2013 | EP2638060A2 Highly immunogenic hiv p24 sequences |
| 09/18/2013 | EP2638058A1 Enolase peptide conjugate vaccines against staphylococcus aureus |
| 09/18/2013 | EP2637693A2 System and method for generating micro-seismic events and characterizing properties of a medium with non-linear acoustic interactions |
| 09/18/2013 | EP2637692A2 Antibodies to tumor endothelial marker 8 |
| 09/18/2013 | EP2637691A2 Materials and methods for directing an immune response to an epitope |
| 09/18/2013 | EP2637690A2 IMPROVED HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS |
| 09/18/2013 | EP2637689A2 Immunomodulatory methods and systems for treatment and/or prevention of hypertension |
| 09/18/2013 | EP2637688A1 North american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof |
| 09/18/2013 | EP2637687A1 Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis |
| 09/18/2013 | EP2637686A2 Immunomodulatory compositions, methods and systems comprising immunogenic fragments of apob100 |
| 09/18/2013 | EP2637685A1 Immunomodulatory methods and systems for treatment and/or prevention of aneurysms |
| 09/18/2013 | EP2637683A2 Methods for organ regeneration |
| 09/18/2013 | EP2637670A1 Prevention of adverse effects caused by cd3 specific binding domains |
| 09/18/2013 | EP2637666A1 Combination of bevacizumab and 2,2-dimethyl-n-((s)-6-oxo-6,7-dihydro - 5h-dibenzo[b,d]azepin-7-yl)-n'-(2,2,3,3,3-pentafluoro-propyl)-malonamide for the treatment of proliferative disorders |
| 09/18/2013 | EP2637661A1 Use of 2-carboxamide cycloamino urea derivatives in the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members |
| 09/18/2013 | CN1630665B Anti-A beta antibodies and their use |
| 09/18/2013 | CN103314104A Lentiviral vector based immunological compounds against malaria |
| 09/18/2013 | CN103314008A Methods and compositions involving protective staphylococcal antigens |
| 09/18/2013 | CN103313990A Alaninyl maytansinol antibody conjugates |
| 09/18/2013 | CN103313728A CD89 activation in therapy |
| 09/18/2013 | CN103313727A Antibody compositions and methods of use |
| 09/18/2013 | CN103313726A Identification and enrichment of cell subpopulations |
| 09/18/2013 | CN103313725A Adsorption of immunopotentiators to insoluble metal salts |
| 09/18/2013 | CN103313596A Leishmania canine challenge model by sand fly bites |
| 09/18/2013 | CN103308673A A method for predicting the risk of getting a cardiovascular event in a female subject |
| 09/18/2013 | CN103305542A Recombinant phage double expression vector and application |
| 09/18/2013 | CN103305534A Reverse genetics operating system of mink enteritis virus and application thereof |
| 09/18/2013 | CN103305531A Dna-sequence and recombinant production of group 4 major allergens from cereals |
| 09/18/2013 | CN103305523A Trichina Tsp-05904 recombinant protein antigen and preparation method thereof |
| 09/18/2013 | CN103305475A Establishment method and application of enterovirus (EV) 71-gene modification system |
| 09/18/2013 | CN103305474A Porcine pseudorabies virus strain as well as inactivated vaccine and applications thereof |
| 09/18/2013 | CN103305473A Bluetongue virus serum 1 (BTV1) VP2 protein monoclonal antibody (BTV1-4B6), B-cell epitope polypeptide identified by BTV1-4B6 and application of BTV1-4B6 |
| 09/18/2013 | CN103305472A Bluetongue virus serum 1 (BTV1) VP2 protein monoclonal antibody (BTV1-3E8), B-cell epitope polypeptide identified by BTV1-3E8 and application of BTV1-3E8 |
| 09/18/2013 | CN103305471A Monoclonal antibody BTV8-VP2-4D9 resist ant to bluetongue virus serum 8 type VP2 protein, B-cell epitope peptide identified thereby and application |
| 09/18/2013 | CN103305470A Monoclonal antibody BTV8-VP2-3E11 resistant to bluetongue virus serum 8 type VP2 protein, B-cell epitope peptide identified thereby and application |
| 09/18/2013 | CN103304671A Human rotavirus P[8]deltaVP8*-P[6]deltaVP8* recombinant chimeric protein and application thereof |
| 09/18/2013 | CN103304670A Mycobacterium tuberculosis specific fusion protein vaccine AB and preparation and application thereof |
| 09/18/2013 | CN103304667A Humanized anti-beta7 antagonists and uses therefor |
| 09/18/2013 | CN103304663A Single-chain antibody of chicken Newcastle disease virus P protein, preparation method and use of single-chain antibody |
| 09/18/2013 | CN103304646A Mycobacterium tuberculosis candidate antigen polypeptide and application thereof |
| 09/18/2013 | CN103304644A Haemophilus parasuis (Hps) immune protective antigen OppA2 |
| 09/18/2013 | CN103304643A Haemophilus parasuis (Hps) immune protective antigen CdtA |
| 09/18/2013 | CN103304642A Porcine rotavirus delta VP8* subunit recombinant protein and applications thereof |
| 09/18/2013 | CN103304636A Mycobacterium tuberculosis candidate antigen polypeptide and application thereof |
| 09/18/2013 | CN103304631A Nonapeptide with anti-tumour activity |
| 09/18/2013 | CN103301477A Application of escherichia coli succinodehydrogenase iron-sulfur protein SdhB |
| 09/18/2013 | CN103301471A Lyophilized vaccine for porcine rotavirus (PRV) |
| 09/18/2013 | CN103301459A Application of anti-heat shock protein 70 (HSP70) in preventing and/or treating hypertensive heart disease and heart failure |
| 09/18/2013 | CN103301458A Mucosa adjuvant based on deoxyribose nucleic acid (DNA) receptor as well as preparation and application thereof |
| 09/18/2013 | CN103301457A Preparation method for egg yolk antibody inactivated vaccine resisting loach pathogenic vibrio cholerae |
| 09/18/2013 | CN103301456A Oil-in-water yeast beta glucan nano-emulsion adjuvant as well as preparation method and application thereof |
| 09/18/2013 | CN103301455A Porcine circovirus-haemophilus parasuis bivalent inactivated vaccine and preparation process thereof |
| 09/18/2013 | CN103301454A Lyophilized vaccine for classical swine fever |
| 09/18/2013 | CN103301453A Freeze-dried vaccine for porcine reproductive and respiratory syndrome and preparation method thereof |
| 09/18/2013 | CN103301452A Lyophilized vaccine for swine encephalitis B and preparation method thereof |
| 09/18/2013 | CN103301451A Brucellin live vaccine freezing-drying protecting agent for intradermal injection |
| 09/18/2013 | CN103301450A Plague live vaccine freezing-drying protecting agent for percutaneous scarification |
| 09/18/2013 | CN103301449A Preparation method of large-scale culture dendritic cell vaccine and application thereof |
| 09/18/2013 | CN102813932B Duck viral hepatitis egg yolk antibody cryoprotectant |
| 09/18/2013 | CN102787100B High-prolificacy porcine circovirus type-2 strain and application thereof |
| 09/18/2013 | CN102731623B Murine original monoclonal antibody 3D8 identified hantaan virus glycoprotein neutralizing epitope peptide and application thereof |
| 09/18/2013 | CN102580085B Application of VEGF (Vascular Endothelial Growth Factor) receptor fusion protein in preparation of medicament treating sepsis |
| 09/18/2013 | CN102552893B Chicken Eimeria tenella actin depolymerizing factor (ADF) recombinant bacillus calmette-guerin and preparation method thereof |
| 09/18/2013 | CN102358751B Human fibrinogen-like protein 2 prothrombinase immunogenicity peptide and use thereof |
| 09/18/2013 | CN102293743B Lipid microsphere composition |
| 09/18/2013 | CN102268455B CEA (chorioembryonic antigen) recombinant adeno-associated viral vector, constructing method thereof and application thereof |
| 09/18/2013 | CN102127150B Nestin portion polypeptide and application thereof |
| 09/18/2013 | CN101948540B Preparation of novel anti-EGFR human source antibody MIL27 and application thereof |
| 09/18/2013 | CN101856496B Placenta stem-cell anti-tumor vaccine, preparation method and application thereof |
| 09/18/2013 | CN101657463B Development of dengue virus vaccine components |
| 09/18/2013 | CN101573449B A DNA vaccine for curing chronic hepatitis b and a method of preparing same |
| 09/18/2013 | CN101300272B Compositions and methods for treating proliferative disorders |
| 09/18/2013 | CN101282994B Anti-CD26 antibodies and methods of use thereof |
| 09/18/2013 | CN101282742B Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment |
| 09/18/2013 | CN101134102B 5T4 antigen-expressed vector |